ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

$20.95 -0.29 (-1.37%)

Closing price 07/3/2025 03:39 PM Eastern

Extended Trading

$20.95 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

ACADIA Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 17 Analyst Ratings

Sell
0

Hold
6

Buy
11

Based on 17 Wall Street analysts who have issued ratings for ACADIA Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 6 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for ACAD.

Consensus Price Target

$27.88
33.05% Upside

According to the 17 analysts' twelve-month price targets for ACADIA Pharmaceuticals, the average price target is $27.88. The highest price target for ACAD is $38.00, while the lowest price target for ACAD is $20.00. The average price target represents a forecasted upside of 33.05% from the current price of $20.95.

Get the Latest News and Ratings for ACAD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors.

ACAD Analyst Ratings Over Time

Type	Current Forecast 7/4/24 to 7/4/25	1 Month Ago 6/4/24 to 6/4/25	3 Months Ago 4/5/24 to 4/5/25	1 Year Ago 7/5/23 to 7/4/24
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)	13 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	8 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$27.88	$26.83	$23.93	$28.71
Forecasted Upside	33.05% Upside	23.26% Upside	55.61% Upside	84.13% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ACAD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ACAD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ACADIA Pharmaceuticals Stock vs. The Competition

Type	ACADIA Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.80	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	33.05% Upside	8,522.19% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent ACAD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/26/2025	Oppenheimer 3 of 5 stars	Matthew Hershenhorn Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00	-2.89%
6/26/2025	JMP Securities 2 of 5 stars	Jason Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00	+64.34%
6/26/2025	Needham & Company LLC 2 of 5 stars	Ami Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00	+33.33%
6/26/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00	+42.22%
6/23/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$26.00 ➝ $38.00	+71.76%
6/6/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tessa Romero Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$26.00 ➝ $30.00	+36.09%
6/5/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Kim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Hold	$18.00 ➝ $23.00	+5.65%
5/21/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Hoang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00	+61.36%
5/20/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jeffrey Hung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00	+9.14%
Get the Latest News and Ratings for ACAD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
5/19/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joel Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$28.00 ➝ $31.00	+42.46%
5/19/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Uy Ear Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$20.00 ➝ $23.00	+5.70%
5/19/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$24.00 ➝ $28.00	+27.60%
4/28/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ashwani Verma Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$25.00 ➝ $22.00	+50.07%
1/3/2025	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Suneja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$23.00 ➝ $20.00	+7.18%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$30.00 ➝ $23.00	+48.67%
5/9/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$26.00 ➝ $21.00	+30.84%
8/3/2023	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$39.00 ➝ $38.00	+36.01%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:19 AM ET.

ACAD Forecast - Frequently Asked Questions

: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for ACADIA Pharmaceuticals is $27.88, with a high forecast of $38.00 and a low forecast of $20.00.
: 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 6 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACAD shares.
: According to analysts, ACADIA Pharmaceuticals's stock has a predicted upside of 33.05% based on their 12-month stock forecasts.
: Over the previous 90 days, ACADIA Pharmaceuticals's stock had 2 upgrades by analysts.
: ACADIA Pharmaceuticals has been rated by research analysts at Bank of America, BMO Capital Markets, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Robert W. Baird, Royal Bank Of Canada, and UBS Group in the past 90 days.
: Analysts like ACADIA Pharmaceuticals less than other "medical" companies. The consensus rating score for ACADIA Pharmaceuticals is 2.71 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ACAD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ACAD) was last updated on 7/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target